Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-11-27 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
曲靖市康桥医药有限责任公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed auditor statements, responsibilities, and an explicit audit opinion by certified public accountants. The document includes comprehensive financial statements such as the balance sheet, income statement, and cash flow statement for the period ending October 31, 2016, and the ten months of 2016. The presence of detailed audit procedures, auditor's opinion, and financial statements confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is Audit Report / Information (AR).
2016-11-27 Chinese
2016年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2016 fourth extraordinary shareholders' meeting of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on a specific loan proposal, and legal witness statements. The content focuses on the official announcement of the shareholders' meeting resolutions and voting outcomes, rather than presenting a full report or financial statements. The document length is relatively short (2168 characters), and it serves as an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-11-15 Chinese
2016年第四次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, and voting procedures of a specific shareholders' meeting (the 2016 fourth extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed. It does not contain financial statements, earnings data, or management discussion. It is not a report itself but a legal opinion on the meeting process and results. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation of shareholder meeting procedures and voting outcomes.
2016-11-15 Chinese
2016年第四次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the 2016 Fourth Extraordinary General Meeting of Shareholders of KPC Pharmaceuticals, Inc. It contains detailed agenda items, voting procedures, and specific proposals to be voted on by shareholders, including a loan proposal. The content is focused on the meeting itself, including procedural rules, agenda, and voting details, rather than the results of the vote or a summary report. This matches the description of materials shared during a general meeting, specifically an Extraordinary General Meeting (EGM) or similar. The document is not a report of voting results (DVA), nor is it a proxy solicitation (PSI), but rather the meeting information and materials provided to shareholders for the meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is 5448 characters, which is consistent with detailed meeting materials rather than a brief announcement or a full annual report.
2016-11-01 Chinese
八届二十一次董事会决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various company matters such as project approvals, investments, acquisitions, and plans for a shareholders meeting. The text includes phrases like '董事会决议公告' (Board of Directors Resolution Announcement) and lists specific board decisions with voting outcomes. There is no financial data, earnings information, or detailed report content. The document is clearly an announcement of board/management decisions rather than a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, confirming this classification.
2016-10-27 Chinese
关于召开2016年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2016 fourth extraordinary general meeting of shareholders for Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. It does not contain financial statements or detailed financial analysis but is an announcement related to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is short and focused on meeting notice and proxy details, not the actual voting results or financial reports.
2016-10-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.